Gustavo B Baretton
Overview
Explore the profile of Gustavo B Baretton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1824
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steinhauser C, Yakac A, Markgraf W, Kromnik S, Docke A, Talhofer P, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408610
To identify potentially transplantable organs in a pool of marginal kidneys, 33 porcine slaughterhouse kidneys were perfused for 4 h with whole blood. During the normothermic perfusion, plasma, urine, and...
2.
Honscheid P, Baretton G, Puhr M, Siciliano T, Israel J, Stope M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273225
Cancer-associated fibroblast (CAF)s in the tumour microenvironment (TME) modulate the extracellular matrix, interact with cancer cells, and facilitate communication with infiltrating leukocytes, significantly contributing to cancer progression and therapeutic response....
3.
Beier A, Ebersbach C, Siciliano T, Scholze J, Hofmann J, Honscheid P, et al.
Oncogene
. 2024 May;
43(26):2038-2050.
PMID: 38750263
Docetaxel (DX) serves as a palliative treatment option for metastatic prostate cancer (PCa). Despite initial remission, acquired DX resistance is inevitable. The mechanisms behind DX resistance have not yet been...
4.
Rade M, Kreuz M, Borkowetz A, Sommer U, Blumert C, Fussel S, et al.
Mol Med
. 2024 Feb;
30(1):19.
PMID: 38302875
Background: Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic...
5.
Linge A, Patil S, Grosser M, Lohaus F, Gurtner K, Kemper M, et al.
Radiother Oncol
. 2023 Dec;
191:110055.
PMID: 38109944
Purpose: To assess the robustness of prognostic biomarkers and molecular tumour subtypes developed for patients with head and neck squamous cell carcinoma (HNSCC) on cell-line derived HNSCC xenograft models, and...
6.
Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, et al.
J Cancer Res Clin Oncol
. 2023 Oct;
149(17):16231-16238.
PMID: 37874352
As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area of cancers of the esophagus,...
7.
Sommer U, Grosser M, Aust D, Joehrens K, Boehm K, Thomas C, et al.
Anticancer Res
. 2023 Sep;
43(10):4365-4371.
PMID: 37772561
Background/aim: PD-L1 inhibitors have been approved for cisplatin-ineligible urothelial cancer patients relapsing after radical cystectomy. A prerequisite for therapy is a positive PD-L1 expression in the tumor tissue, whereas no...
8.
Schimmelpfennig C, Rade M, Fussel S, Loffler D, Blumert C, Bertram C, et al.
BMC Cancer
. 2023 Jun;
23(1):575.
PMID: 37349736
Background: Prostate cancer (PCa) is one of the most prevalent cancers worldwide. The clinical manifestations and molecular characteristics of PCa are highly variable. Aggressive types require radical treatment, whereas indolent...
9.
Aust D, Baretton G, Sommer U
Pathologie (Heidelb)
. 2023 Jun;
44(5):294-300.
PMID: 37311872
Ulcerative colitis (UC) is a chronic inflammatory bowel disease beginning in the rectum and gradually extending to the right-sided colon and the terminal ileum (backwash-ileitis). Its causes are still not...
10.
Galli R, Siciliano T, Aust D, Korn S, Kirsche K, Baretton G, et al.
Sci Rep
. 2023 Mar;
13(1):4274.
PMID: 36922643
As the state of resection margins is an important prognostic factor after extirpation of colorectal liver metastases, surgeons aim to obtain negative margins, sometimes elaborated by resections of the positive...